FLT3 and systemic mastocytosis: On the other hand, a phase III trial of midostaurin plus standard chemotherapy in mutant FLT3-positive AML patients [56] and a phase II trial of midostaurin alone in patients with advanced systemic mastocytosis [61] exhibited significant clinical benefits, such as enhanced overall response rate, prolonged event-free survival, and low unexpected toxicity.